#ESMO22 Presidential Symposium III continued with the eagerly awaited #CodeBreak200 evaluating sotorasib vs docetaxel in pts w/ locally advanced or metastatic KRAS G12C-mutated NSCLC (N=345) presented by @MLJohnsonMD2 from @SarahCannonDocs Image
#ESMO22 #CodeBreak200 met it's primary EP of improved PFS by BICR with a median f/u of 17.7 mo. Median PFS: 5.6 vs 4.5 mo, HR=0.66, P=.002 ImageImage
#ESMO22 #CodeBreak200 ORR was higher in pts treated with sotorasib (28.1 vs 13.2%) and mDOR was longer with sotorasib (8.6 vs 6.8 mo). There was no difference in OS ImageImageImage
#ESMO22 #CodeBreak200 There were fewer gr3 or higher AEs with sotorasib and diarrhea, nausea, and decreased appetite were most common AEs ImageImage
#ESMO22 #CodeBreak200 demonstrated that targeting KRAS G12C advanced NSCLC with #sotorasib improved PFS and response although the magnitude of benefit was smaller than anticipated. The study was discussed by Natasha Leighl from @UofT @pmcancercentre ImageImage

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Cancer Conference News

Cancer Conference News Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @FrontRowCME

Sep 13
#ESMO22 final Presidential Symposium III presentation, #IPSOS, evaluating atezolizumab vs single-agent chemotherapy in pts with advanced NSCLC unsuitable for 1L standard platinum-based chemotherapy, N=453, primary EP: OS ImageImage
#ESMO22 #IPSOS with a median f/u of 41 mo, atezolizumab monotherapy resulted in significantly improved OS (mOS: 10.3 vs 9.3 mo; HR-0.78; P=.028). The improved was seen across subgroups and independent of PD-L1 expression ImageImage
#ESMO22 #IPSOS ORR (16.9% vs 7.9%) and DOR (14.0 vs 7.8 mo) were better with atezo, but no significant difference in PFS was found ImageImage
Read 6 tweets
Sep 13
#ESMO22 COSMIC-313 presented by @DrChoueiri Triplet therapy with cabo/nivo/ipi vs cabo/nivo for patients with advanced TN advanced intermediate or poor-risk #RCC. Primary EP: PFS; N=855 Image
#ESMO22 #COSMIC313: Longer PFS with triplet vs doublet. mPFS NR vs 11.3 mo with benefit seen in most predefined subgroups #RCC ImageImageImage
#ESMO22 #COSMIC313 ORR 43% vs 36% with 3% CR in both arms; mDOR not reached in either arm #RCC ImageImage
Read 6 tweets
Sep 10
#ESMO22 Presidential Symposium 1 LBA3 TIL vs ipilimumab for advanced melanoma, phase 3 study @HaanenJohn @OncoAlert @myESMO
Unresectable stage IIC-IV melanoma progression with a max of 1 line of prior systemic treatment (not ipi), N = 168, randomized 1:1 TIL vs ipilimumab. Primary EP = PFS; Most pts had prior anti PD-1 treatment ImageImageImage
PFS significantly improved with TIL vs ipi (Median PFS: 7.2 vs 3.1 mo). HR = 0.50, P < .001. The majority of predefined subgroups benefited from TIL ImageImage
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(